6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

      Gastroenterology

      Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Germany, epidemiology, Hepatorenal Syndrome, drug therapy, mortality, physiopathology, Humans, Injections, Intravenous, Kidney Function Tests, Lypressin, administration & dosage, analogs & derivatives, Male, Middle Aged, Prospective Studies, Russia, Severity of Illness Index, Shock, Septic, Survival Rate, Treatment Outcome, United States, Vasoconstrictor Agents

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hepatorenal syndrome (HRS) type 1 is a progressive functional renal failure in subjects with advanced liver disease. The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor, for cirrhosis type 1 HRS. A prospective, randomized, double-blind, placebo-controlled clinical trial of terlipressin was performed. Subjects with type 1 HRS were randomized to terlipressin (1 mg intravenously every 6 hours) or placebo plus albumin in both groups. The dose was doubled on day 4 if the serum creatinine (SCr) level did not decrease by 30% of baseline. Treatment was continued to day 14 unless treatment success, death, dialysis, or transplantation occurred. Treatment success was defined by a decrease in SCr level to

          Related collections

          Author and article information

          Journal
          18471513
          3730280
          10.1053/j.gastro.2008.02.014

          Comments

          Comment on this article